特集 神経疾患治療の進歩2024
認知症の治療の進歩
2025 年 42 巻 5 号 p. 799-802
詳細
2025 年 42 巻 5 号 p. 799-802
In 2024, following lecanemab in 2023, donanemab was approved and we have two types of anti–amyloid antibody drugs available for patients with Alzheimer disease in clinical settings in Japan. A number of agents are in development that target the causative proteins of neurodegenerative diseases such as tau, α–synuclein in addition to amyloid–β. In this article, we describe the results or plans of clinical studies relevant to amyloid–β, tau and α–synuclein that have been newly reported in 2024.
